Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isavuconazole + ketoconazole is a combination of two antifungal agents, both classified as triazole antifungals. **Isavuconazole** is the active moiety of the prodrug isavuconazonium sulfate and inhibits the cytochrome P450–dependent enzyme lanosterol 14α-demethylase, blocking ergosterol synthesis and impairing fungal cell membrane integrity, leading to cell death[2][4]. **Ketoconazole** operates via the same mechanism, inhibiting fungal lanosterol 14α-demethylase and also acts as a strong inhibitor of CYP3A4 in humans. When coadministered, **ketoconazole significantly increases exposure to isavuconazole** via potent inhibition of isavuconazole's CYP3A4 metabolism[1][3][5]. This combination is not formulated or marketed as a fixed-dose product, but may occur as a result of concomitant use. Isavuconazole is primarily used for invasive aspergillosis and mucormycosis; ketoconazole (oral) is generally reserved for non-systemic fungal infections due to toxicity risks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isavuconazole + ketoconazole.